Harry DeMott, the CEO of beleaguered cannabis firm Australis Capital (AUSA) (CSE:AUSA,OTCQB:AUSAF), has told shareholders Terry Booth is vying for his job.

In the lead-up to a crucial shareholder vote to determine the future of the company, AUSA management hosted a conference call last Thursday (October 29) to continue making its case to undecided investors.

“I think investors who are thinking about going with Terry are being asked to trust him, and I think trust has been sort of a four letter word with Terry,” DeMott said during the call.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Booth, the founder and former CEO of Aurora Cannabis (NYSE:ACB,TSX:ACB), is at the forefront of the Concerned Shareholders of Australis Capital, a group seeking material changes at AUSA. DeMott suggested Booth will be appointed to AUSA’s board of directors if his dissident group wins the shareholder vote.

The group has countered AUSA’s board nominees with its own set of candidates; the vote will happen as part of the company’s upcoming annual general and special meeting on November 17.

Both AUSA and the Concerned Shareholders have sent out documents and materials on their respective board nominees. Now it’s an election-type march with back-and-forths between the groups heading into the vote.

AUSA was originally spun out of Aurora as a separate company looking to invest in the US cannabis market. Aurora still holds 22 million AUSA warrants, and they have an exercisable deadline of September 19, 2028.

Aurora can’t exercise these warrants until cannabis is federally legal in the US, given its position as a Canadian producer with senior exchange listings in both countries.

When detailing the state of affairs for AUSA, DeMott indicated the company counts three key cannabis assets: its kiosk business venture, its current share ownership in Body and Mind (CSE:BAMM,OTCQB:BMMJ), which has exposure to Nevada and California, and a recently acquired cannabis brand portfolio.

“That’s number one, clean up the assets we have. We have good cannabis assets, there’s no reason we shouldn’t maximize them,” he said.

The executive spent some time sharing his evaluation of the fractured US market, which the company still plans to focus on. “It’s very much so a wild west show in the US,” he said.

DeMott said companies operating in the US need to be careful before deploying capital for hard assets such as growing facilities or dispensaries given the regulation changes seen at the state and even city level.

“We are very wary of regulations and jurisdictions that we’re in to try and understand where we’re going,” the executive told investors.

SPAC intentions and DeMott’s background take center stage

In a new strategy presentation made available to investors, AUSA outlines its intentions to pursue the increasingly popular special-purpose acquisition company (SPAC) model. According to the document, the company plans to “raise a small SPAC” in the range of C$75 million to C$100 million.

However, during last Thursday’s call, DeMott said that move is not confirmed, instead noting that AUSA’s management team plans to explore the feasibility of launching a SPAC.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“If we did it, we would use some money from Australis to become part of the sponsor, and therefore Australis would get part of the sponsor shares, therefore shareholders would benefit,” he said.

SPACs raise capital by presenting an acquisition strategy to investors with a proposed timeline attached. Once the qualifying transaction is completed, the investors get shares in return; if the transaction is not completed on time, investors get their money back.

DeMott was also asked during the call to expand on his knowledge of the cannabis industry — a point of contention as the Concerned Shareholders have routinely called into question his experience and management style.

DeMott’s closest connection to the cannabis business comes from acting as an early investor with Columbia Care, a multi-state operator in the US that started its journey in the capital market as a SPAC. The executive said he still holds about 16 percent ownership of Columbia Care’s license in Washington, DC, amongst shares in Columbia Care. “I’ve always been entrepreneurial in nature,” DeMott said to listeners.

In an attempt to level with investors about his true intentions with the company, the leading executive said his pay is about half of what the previous CEO Scott Dowty was earning. DeMott started the job of CEO on October 5, but has been involved with AUSA since he was appointed as a board member in April 2019.

In addition to his salary, DeMott said he asked “for as many options as the board was willing to give me” as part of his compensation. He didn’t disclose how many that amounts to in the call.

According to Canadian Insider transaction files, DeMott bought an additional 30,000 shares of the company at a price of C$0.11 per unit at the start of October. The filing indicates he held a closing balance of 130,000 shares at the time.

DeMott used his salary as to demonstrate that his goal is to raise AUSA’s share price. “We want to bet on ourselves and our ability to get things done,” he said.

Investor takeaway

In the week since the call with investors took place, shares of AUSA have dropped in value by nearly 4 percent. As of 1:45 p.m. EST this Thursday (November 5), the company was trading at C$0.12 per share.

While the official AUSA shareholder meeting will be on November 17, investors have a deadline to vote before November 13 at 11:30 a.m. MT.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less